Cefodizime: Broad-Spectrum Cephalosporin for Antibacterial Research

Executive Summary: Cefodizime is a third-generation cephalosporin antibiotic with broad-spectrum activity against both Gram-positive and Gram-negative bacteria, including key clinical isolates such as Escherichia coli and Haemophilus influenzae (APExBIO; MaltosePharma 2023). It is stable against most β-lactamases, enhancing its efficacy in resistance studies (CefazolinAPIS 2023). Cefodizime exerts its bactericidal effect by inhibiting penicillin-binding proteins and disrupting cell wall synthesis (Survivin-Baculoviral IAP 2023). Its immunomodulatory properties augment host phagocytic cell function. The compound is predominantly eliminated via the renal route, making it a preferred choice in kidney-safe infection models (APExBIO).

Biological Rationale

Cefodizime (CAS No. 69739-16-8) is classified as a third-generation cephalosporin antibiotic. Its broad-spectrum antibacterial activity covers a range of clinically relevant Gram-positive bacteria, including methicillin-sensitive Staphylococcus aureus (MSSA) and streptococci, as well as Gram-negative bacteria such as members of the Enterobacteriaceae family, Haemophilus influenzae, and Neisseria species (APExBIO). Cefodizime’s resistance to most β-lactamases allows it to maintain activity in the presence of common resistance mechanisms. Its immunomodulatory effects, including enhancement of phagocyte function, provide added value for translational infectious disease research (CefazolinAPI 2023). This antibiotic is kidney-safe, with 56–80% of the administered dose excreted via urine within 24 hours (APExBIO).

Mechanism of Action of Cefodizime

Cefodizime acts by binding to and inhibiting bacterial penicillin-binding proteins (PBPs), notably PBPs 1A/B, 2, and 3 in E. coli (APExBIO). This interaction disrupts the final stages of peptidoglycan synthesis, leading to cell wall structural loss and bacterial lysis. The action is bactericidal and is effective against bacteria in both exponential and stationary phases (Survivin-Baculoviral IAP 2023). The molecule’s stability against β-lactamase hydrolysis is due to its unique side chain modifications. Additionally, cefodizime enhances innate immune responses by augmenting phagocytic cell activity, as demonstrated in preclinical models (CefazolinAPI 2023).

Evidence & Benchmarks

• Cefodizime inhibits 90% of Escherichia coli strains at 0.40 mg/L (MIC₉₀) in vitro (APExBIO).
• MIC₉₀ for Haemophilus influenzae: <0.01 mg/L; for Neisseria gonorrhoeae: 0.008–0.016 mg/L (APExBIO).
• Stable against β-lactamases, including penicillinases and cephalosporinases (CefazolinAPIS 2023).
• Effective against MSSA and streptococci, but not MRSA or Pseudomonas aeruginosa (APExBIO).
• Elimination half-life: 2–5 hours; plasma protein binding: 81% (APExBIO).
• Urinary excretion: 56–80% within 24 hours post-administration (APExBIO).
• Demonstrated immunomodulatory enhancement of phagocytic cell function in vitro and in vivo (CefazolinAPI 2023).
• Clinical cure rates for respiratory/urinary tract infections: 80–100% in adult and pediatric research cohorts (APExBIO).

Applications, Limits & Misconceptions

Cefodizime is widely used in research models of respiratory and urinary tract infections due to its broad-spectrum efficacy and favorable pharmacokinetics. Its β-lactamase stability makes it valuable in resistance mechanism studies and for benchmarking new β-lactam derivatives (MeropenemAPI 2023). Compared to previous reviews, this article offers updated, quantitative MIC values and practical laboratory integration guidelines. Cefodizime’s immunomodulatory effects can be leveraged in host-pathogen interaction studies, extending the applications discussed in immunomodulation-focused analyses.

Common Pitfalls or Misconceptions

• Cefodizime is ineffective against Pseudomonas aeruginosa and MRSA—do not use for these targets (APExBIO).
• Not intended for diagnostic or therapeutic use in humans or animals; for research use only (APExBIO).
• Some ESBL-producing Enterobacteriaceae may show resistance—verify strain susceptibility before use (CefazolinAPIS 2023).
• Solubility is high in DMSO (≥51.1 mg/mL) but negligible in water or ethanol; improper solvents reduce assay reproducibility (APExBIO).
• Contraindicated in cephalosporin-allergic models or systems.

Workflow Integration & Parameters

For research applications, Cefodizime (APExBIO BA1050) is provided as a solid and is DMSO-soluble (≥51.1 mg/mL). Typical working concentrations in antibacterial activity assays range from 0.001–8 mg/L, matching clinical breakpoint references. Adult research models use 1–4 g/day via intravenous or intramuscular routes, with pediatric dosages adjusted by weight. Store at -20°C to maintain compound stability. For resistance studies, combine with β-lactamase-producing strains to benchmark efficacy. Quantitative MIC testing and time-kill curves are recommended for robust data. For further practical guidelines and troubleshooting, see MeropenemAPI 2023, which APExBIO's Cefodizime kit extends by delivering validated, batch-to-batch reproducibility.

Conclusion & Outlook

Cefodizime is a validated third-generation cephalosporin antibiotic for broad-spectrum antibacterial research. Its proven β-lactamase stability and immunomodulatory properties recommend it for advanced studies in resistance and host-pathogen interaction. APExBIO’s supply of Cefodizime (BA1050) ensures consistent performance in microbiology and infectious disease research workflows. Future studies may further define its immunomodulatory effects and refine its use in complex infection models.